Investor Relations

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. 

There are no items to display.
Date Title and Summary
Toggle Summary Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates
-- $50 million opt-in payment for CD19 program to Juno -- SUMMIT, N.J. & SEATTLE --(BUSINESS WIRE)--Apr. 11, 2016-- Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that Celgene exercised its option to develop and commercialize the Juno CD19 program
Toggle Summary Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases
Broad strategic collaboration leveraging combined immunology expertise and assets to develop and commercialize novel immunotherapies for the treatment of cancer and autoimmune diseases Celgene gains option to commercialize Juno programs outside North America and co-promote certain programs globally
Toggle Summary CORRECTING and REPLACING JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy
Patients who received a dose of CD19 targeted defined composition engineered T cells after chemotherapy went into complete remission SEATTLE --(BUSINESS WIRE)--Sep. 7, 2016-- In the contact information of the release, the email address for Christopher Williams should read:
Toggle Summary Court Decides It Lacks Jurisdiction Before FDA Approval Occurs
SEATTLE --(BUSINESS WIRE)--Jun. 14, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, announced today that the U.S. District Court for the District of Delaware decided it lacked jurisdiction at this

UPCOMING & PAST EVENTS

View all events

Copyright Nasdaq. Minimum 15 minutes delayed.